Every Clarivant Health report is produced through a structured four-stage methodology: primary source assembly, bottom-up market construction, analyst validation, and editorial review.
Healthcare market intelligence often relies on repeated estimates that trace back to undisclosed methods or unverified syndicated sources. When several reports arrive at similar numbers, the underlying evidence can still be weak if the figures are citing each other.
Clarivant Health Intelligence is built to produce market intelligence that can withstand scrutiny from diligence teams, licensing groups, strategy committees, procurement leaders, and investment committees. Every market size figure, share estimate, pipeline count, and pricing datapoint must be traceable to a named source or a documented construction method.
Not for clinical use. Clarivant Health Intelligence provides market intelligence for business, strategy, and investment purposes only. No content produced under this methodology is intended for clinical decision-making, patient care, prescribing, or any medical purpose.
Every Clarivant Health report follows these stages in sequence. No stage is optional.
The analyst assembles the relevant primary sources before analysis begins. Geography, product boundaries, end-user definition, and base year are fixed at this stage so estimates stay internally consistent.
Market sizes are constructed from disclosed revenue lines, procedure volume data, device clearance counts, pricing research, reimbursement schedules, and documented proxy methods where direct disclosure is not available.
Key assumptions are validated through structured expert inputs. The purpose is not to collect anecdotal market size numbers, but to test assumptions where data is incomplete, recent, or commercially nuanced.
A second senior analyst reviews factual accuracy, source attribution, internal consistency, forecast arithmetic, and compliance with the not-for-clinical-use content standard before publication.
Sources are checked against their original public record wherever possible. Trade press is used for monitoring events, not as a primary source for market size or share estimates.
| Source category | Specific sources | Verification standard |
|---|---|---|
| Company financial filings | Annual reports, 10-K / 20-F filings, SEC EDGAR, investor presentations, earnings call transcripts | Revenue figures are used from audited filings or verified earnings disclosures. Segment revenue is used where disclosed; proxy methods are documented. |
| Regulatory databases | FDA 510(k), PMA, De Novo, CDER approvals, BLA and NDA submissions, EMA records | Clearance dates, product descriptions, and approval status are checked against agency records and source documents. |
| Reimbursement data | CMS DMEPOS, OPPS, Physician Fee Schedule, Medicare claims data, LCD and NCD determinations | Rates and effective dates are verified against published final rules, fee schedules, and policy documents. |
| Clinical trial registries | ClinicalTrials.gov, EudraCT, ISRCTN, WHO International Clinical Trials Registry Platform | Trial status, phase, enrolment, endpoints, and sponsor are verified from registry records rather than press release claims. |
| Health statistics | CDC, WHO Global Health Observatory, CMS National Health Expenditure, OECD Health Statistics, NHS Digital | Epidemiological figures are used for market sizing context only and are attributed to the named agency and report year. |
| Trade press monitoring | MedTech Dive, STAT News, Fierce Biotech, MedCity News, Pink Sheet, FDA Week | Used to identify recent developments and then cross-checked against company, agency, or regulatory sources. |
These are operating constraints applied to every published report and checked during peer review.
We do not use Grand View Research, MarketsandMarkets, Mordor Intelligence, IMARC, Statista, or other syndicated market-research publishers as primary data sources. If a figure cannot be traced to primary evidence, it is excluded or rebuilt.
Market sizes are not derived by applying a macro growth rate or regional income multiplier. They are built from revenue, volume, price, reimbursement, or demand components.
Clinical and epidemiological data is used to contextualise markets, not to advise on patient care, treatment choices, prescribing, or clinical protocols.
Published market size estimates, competitive assessments, and analytical conclusions are written and reviewed by human analysts.
Market size, share, pipeline, pricing, and forecast figures carry a source citation or a methodology note explaining how the figure was constructed.
Directly disclosed company figures and analyst-derived estimates are labelled differently so readers know where evidence ends and estimation begins.
Product status is checked against FDA, EMA, or relevant national agency records at the time of publication.
No report is published without review by a second analyst who checks evidence, arithmetic, source attribution, and content framing.
Forecasts are structured estimates based on documented inputs. They are not guarantees of future performance.
Assumes current regulatory, reimbursement, and competitive conditions continue. Growth is derived from pipeline volume, addressable demand, pricing, and adoption trends.
Regulatory approvals, reimbursement expansion, clinical guideline support, product launches, and geographic penetration are assessed for probability and magnitude.
Rate pressure, prior authorisation burden, competition, supply chain disruption, patent expiry, and regulatory action are applied as documented constraints.
CAGR is calculated from the verified base year value to the end-of-period forecast value. It is not back-calculated to fit a target growth story.
The base year is the most recent period with verified company revenue data available at production time, typically the most recently completed fiscal year.
Market sizes are reported in USD unless stated otherwise. Non-USD revenue is converted using average exchange rates for the reporting period.
Forecast limitation notice. Market forecasts reflect analyst judgement at the time of publication based on available evidence. Healthcare market conditions can change materially after a report is published, so forecasts should be treated as structured planning estimates, not financial projections.
A market size estimate without an explicit scope definition is a number without a denominator. We define scope before we size.
Every market size, share estimate, and pipeline datapoint is traced to a named source before peer review.
Segment totals, shares, and geographic splits are checked against the overall market estimate.
Product status is checked against agency databases close to the report publication date.
Language that could be read as clinical guidance is revised into business and market-context framing.
Growth rates are recalculated from stated market size endpoints before publication.
Source citations follow the Clarivant format: named source, document type, publication date, and construction note where required.
A rigorous methodology reduces uncertainty, but it does not remove it. Some markets have limited primary disclosure, especially private-company-dominated categories and early-stage technology markets. In those cases, proxy methods and estimation ranges are documented.
Expert interviews validate assumptions, but they are not statistically representative surveys. Forecasts remain estimates of likely future conditions, not predictions or guarantees.
